Terms: = Prostate cancer AND ARID1B, 6A3-5, 57492, ENSG00000049618, p250R, KIAA1235, ELD/OSA1, DAN15, BRIGHT, BAF250b
98 results:
1. Keeping your best options open with AI-based treatment planning in prostate and cervix brachytherapy.
Dickhoff LRM; Scholman RJ; Barten DLJ; Kerkhof EM; Roorda JJ; Velema LA; Stalpers LJA; Pieters BR; Bosman PAN; Alderliesten T
Brachytherapy; 2024; 23(2):188-198. PubMed ID: 38296658
[TBL] [Abstract] [Full Text] [Related]
2. Hotspots and frontiers in PSMA research for prostate cancer: a bibliometric and visualization analysis over the past 20 years.
Zhang H; Xiao L; Xie H; Li L
Eur J Med Res; 2023 Dec; 28(1):610. PubMed ID: 38115121
[TBL] [Abstract] [Full Text] [Related]
3. Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [
Mirshahvalad SA; Eisazadeh R; Shahbazi-Akbari M; Pirich C; Beheshti M
Semin Nucl Med; 2024 Jan; 54(1):171-180. PubMed ID: 37752032
[TBL] [Abstract] [Full Text] [Related]
4. Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/arid1b co-inactivated dedifferentiated endometrial carcinoma.
Wong NKY; Llaurado Fernandez M; Kommoss FKF; Praveen Kumar P; Kim H; Liu J; Zhang G; Coatham M; Lin YY; Haegert AM; Volik S; Le Bihan S; Collins CC; Fu Y; Postovit LM; von Deimling A; Wu R; Xue H; Wang Y; Köbel M; Carey MS; Lee CH
Gynecol Oncol; 2023 Sep; 176():162-172. PubMed ID: 37556934
[TBL] [Abstract] [Full Text] [Related]
5. Automated Ki-67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry.
Blessin NC; Yang C; Mandelkow T; Raedler JB; Li W; Bady E; Simon R; Vettorazzi E; Lennartz M; Bernreuther C; Fraune C; Jacobsen F; Krech T; Marx A; Lebok P; Minner S; Burandt E; Clauditz TS; Wilczak W; Sauter G; Heinzer H; Haese A; Schlomm T; Graefen M; Steurer S
J Pathol; 2023 May; 260(1):5-16. PubMed ID: 36656126
[TBL] [Abstract] [Full Text] [Related]
6. Towards artificial intelligence-based automated treatment planning in clinical practice: A prospective study of the first clinical experiences in high-dose-rate prostate brachytherapy.
Barten DLJ; Pieters BR; Bouter A; van der Meer MC; Maree SC; Hinnen KA; Westerveld H; Bosman PAN; Alderliesten T; van Wieringen N; Bel A
Brachytherapy; 2023; 22(2):279-289. PubMed ID: 36635201
[TBL] [Abstract] [Full Text] [Related]
7. Problem-solving skills training in adult cancer survivors: bright IDEAS-AC pilot study.
Noyes K; Zapf AL; Depner RM; Flores T; Huston A; Rashid HH; McNeal D; Constine LS; Fleming FJ; Wilding GE; Sahler OJZ
Cancer Treat Res Commun; 2022; 31():100552. PubMed ID: 35358820
[TBL] [Abstract] [Full Text] [Related]
8. Synthesis and photophysical properties of a new push-pull pyrene dye with green-to-far-red emission and its application to human cellular and skin tissue imaging.
Inoue K; Kawakami R; Murakami M; Nakayama T; Yamamoto S; Inoue K; Tsuda T; Sayama K; Imamura T; Kaneno D; Hadano S; Watanabe S; Niko Y
J Mater Chem B; 2022 Mar; 10(10):1641-1649. PubMed ID: 35194628
[TBL] [Abstract] [Full Text] [Related]
9. Using bimetallic Au/Cu nanoplatelets for construction of facile and label-free inner filter effect-based photoluminescence sensing platform for sarcosine detection.
Lin X; Tian M; Cao C; Shu T; Wen Y; Su L; Zhang X
Anal Chim Acta; 2022 Feb; 1192():339331. PubMed ID: 35057923
[TBL] [Abstract] [Full Text] [Related]
10. Upconversion nanoparticle-assisted single-molecule assay for detecting circulating antigens of aggressive prostate cancer.
Chen Y; Shimoni O; Huang G; Wen S; Liao J; Duong HTT; Maddahfar M; Su QP; Ortega DG; Lu Y; Campbell DH; Walsh BJ; Jin D
Cytometry A; 2022 May; 101(5):400-410. PubMed ID: 34585823
[TBL] [Abstract] [Full Text] [Related]
11. A nomogram concerning immune infiltration and radiosensitivity to predict biochemical recurrence after radical radiation therapy in prostate cancer.
Qiu C; Zhou X; Chen Z; Ren H
J BUON; 2021; 26(4):1612-1622. PubMed ID: 34565026
[TBL] [Abstract] [Full Text] [Related]
12. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
Pachynski RK; Morishima C; Szmulewitz R; Harshman L; Appleman L; Monk P; Bitting RL; Kucuk O; Millard F; Seigne JD; Fling SP; Maecker HT; Duault C; Ramchurren N; Hess B; D'Amico L; Lacroix A; Kaiser JC; Morre M; Grégoire A; Cheever M; Yu EY; Fong L
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452927
[TBL] [Abstract] [Full Text] [Related]
13. prostate cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors.
Gallazzi M; Baci D; Mortara L; Bosi A; Buono G; Naselli A; Guarneri A; Dehò F; Capogrosso P; Albini A; Noonan DM; Bruno A
Front Immunol; 2020; 11():586126. PubMed ID: 33569050
[TBL] [Abstract] [Full Text] [Related]
14. cancer burden in China: trends, risk factors and prevention.
Sun D; Li H; Cao M; He S; Lei L; Peng J; Chen W
Cancer Biol Med; 2020 Nov; 17(4):879-895. PubMed ID: 33299641
[TBL] [Abstract] [Full Text] [Related]
15. Image-based phenotyping of disaggregated cells using deep learning.
Berryman S; Matthews K; Lee JH; Duffy SP; Ma H
Commun Biol; 2020 Nov; 3(1):674. PubMed ID: 33188302
[TBL] [Abstract] [Full Text] [Related]
16. Finding "bright Spots": Using Multiple Measures to Examine Local-Area Racial Equity in cancer Mortality Outcomes.
Scott LC; Bartley S; Dowling NF; Richardson LC
Am J Epidemiol; 2021 Apr; 190(4):673-680. PubMed ID: 33073838
[TBL] [Abstract] [Full Text] [Related]
17. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or prostate cancer: A Phase I Study.
Autio KA; Klebanoff CA; Schaer D; Kauh JSW; Slovin SF; Adamow M; Blinder VS; Brahmachary M; Carlsen M; Comen E; Danila DC; Doman TN; Durack JC; Fox JJ; Gluskin JS; Hoffman DM; Kang S; Kang P; Landa J; McAndrew PF; Modi S; Morris MJ; Novosiadly R; Rathkopf DE; Sanford R; Chapman SC; Tate CM; Yu D; Wong P; McArthur HL
Clin Cancer Res; 2020 Nov; 26(21):5609-5620. PubMed ID: 32847933
[TBL] [Abstract] [Full Text] [Related]
18. FDG-PET Versus PSMA-PET: A Patient With prostate cancer.
Kichloo A; Amir R; Aljadah M; Wani F; Solanki S; Singh J; Chugh SS
J Investig Med High Impact Case Rep; 2020; 8():2324709620941313. PubMed ID: 32646251
[TBL] [Abstract] [Full Text] [Related]
19. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B; Sarivalasis A; Lozano LE; Wyss T; Inoges S; de Vries IJM; Dartiguenave F; Jichlinski P; Derrè L; Coukos G; Melero I; Harari A; Romero P; Viganó S; Kandalaft LE
Eur J Cancer; 2020 Aug; 135():173-182. PubMed ID: 32590296
[TBL] [Abstract] [Full Text] [Related]
20. IL-15 in the Combination Immunotherapy of cancer.
Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
Front Immunol; 2020; 11():868. PubMed ID: 32508818
[TBL] [Abstract] [Full Text] [Related]
[Next]
